Blockchain analytics firm Chainalysis reports that suppliers of gray-market peptide drugs are shifting to Bitcoin and stablecoins as their preferred payment methods. This shift is driven by difficulties these vendors face with traditional banking and payment processors, which often reject accounts linked to unregulated pharmaceutical sales. Bitcoin offers a decentralized payment option without banking intermediaries, while stablecoins provide price stability by pegging to the US dollar. Although crypto payments create a permanent, traceable record on public blockchains, this trend poses new challenges for compliance teams and law enforcement tracking semi-legal transactions. The report highlights ongoing regulatory and reputational issues for the crypto industry as certain gray-market sectors increasingly adopt digital assets.
In recognition of National Homeownership Month, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) are advising prospective homebuyers to work with local community banks for guidance. They emphasize steps like securing...
Verizon Communications announced a quarterly dividend of 70.75 cents per share, maintaining the same rate as the previous quarter. The dividend will be paid on August 3, 2026, to shareholders recorded by July 10, 2026. Verizon highlighted its 20 cons...
Guidewire Software reported better-than-expected Q3 results with adjusted earnings of 82 cents per share and revenue of $372.54 million, surpassing analyst estimates. Subscription and support revenue rose 35%, while license revenue slightly declined ...
QBIX, LLC has rebranded as Northbank Technology Group, emphasizing its 23 years of Microsoft ERP expertise and a stronger focus on Microsoft Dynamics 365 Business Central. The company aims to help Northern California businesses modernize their financ...
The US Supreme Court unanimously ruled in favor of Hikma Pharmaceuticals, ending a patent infringement lawsuit filed by Amarin. The dispute involved Hikma's generic icosapent ethyl, a fish oil-based medicine for severe hypertriglyceridemia, which Hik...
